U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Go back to U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 60.76 -0.17 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $60.93 | 52 Week High | $77.12 | |||
| Open | $61.40 | 52 Week Low | $49.03 | |||
| Day High | $61.70 | P/E | 39.45 | |||
| Day Low | $60.56 | EPS | $1.54 | |||
| Volume | 6,796,827 | |||||
